Food Allergy

A study at AAAAI 2025 found that dupilumab led to a 73.5% reduction in IgE levels at 24 months.

Five years after peanut oral immunotherapy, children showed lower allergen-specific IgE and greater IgG4 levels than placebo, indicating sustained immune tolerance.

ADP101 raised food allergy thresholds in children but missed its primary endpoint. Findings support further research into multi-food oral immunotherapy.

A study found no negative effect of food allergies on school performance, with better grades in severe cases, but results were nonsignificant in sibling analyses.

This systematic review and meta-analysis highlighted several key findings on use of probiotics as a treatment of pediatric patients with allergies to food.

The investigators assessed the proportion of households that chose to eliminate allergens by specific allergies to foods and to evaluate related psychosocial functioning among families.

In this analysis, baseline peanut sIgE was shown to be a stronger predictor of remission after peanut OIT than age at the beginning of immunotherapy treatment.

The field of allergy medicine this year saw a variety of developments, including the FDA approvals of neffy and omalizumab as well as new data on immunotherapy.

Kim, Sindher, Huffaker spoke with HCPLive about some of the year’s most important developments in the food allergy space, namely the approvals of omalizumab and neffy.

Findings suggest an association between food allergies and atopic dermatitis control and persistence.

In this analysis, investigators determined that the eliciting dose of an allergen may be an unpredictable marker for the severity of an allergic reaction.

These data highlight some of the most notable findings related to airline travel issues among those with food allergies or with family members with such allergies.

In this analysis, egg consumption among pregnant mothers was found to be insufficient for the development of oral tolerance to eggs among infants at 1 year of age.

In this analysis, the investigators systematically assessed links between the macronutrient profiles of common allergenic foods and corresponding prevalence of food allergy.

In these guidelines compiled by the ACAAI, the AAAAI, and the AAOA, recommendations are provided to insurance companies for documentation needed for allergen immunotherapy.

In this analysis, the benefits of 2’-FL for mothers’ offspring with regard to allergies were highlighted by investigators.

In this review of the month of October, some of the most notable advancements and news in the field of allergy were highlighted.

Aquestive Therapeutics plans to submit an NDA for Anaphylm in Q1 2025 based on topline results from the Oral Allergy Syndrome challenge study.

Findings from the study also continued to support a positive Ara h 2-sIgE as the single most important predictor of peanut allergy.

Incorporating baked milk products into a regular diet may improve growth and quality of life in milk-allergic children.

During situations in which those with severe allergies suffer from fatal anaphylaxis, adrenaline autoinjectors were shown in this study to have little effect on such reactions.

These findings highlight the underrepresentation of Black and Hispanic food allergy clinical trial participants and raise concerns about the generalizability of clinical research findings.

In the allergy news space, this Month in Review highlights some of the most significant stories covered by the editorial team.

Individuals with comorbid asthma and food allergies saw no loss of efficacy in this post hoc analysis, suggesting omalizumab’s potential for such patients.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.